299. Cystic fibrosis Clinical trials / Disease details

Clinical trials : 1,696 / Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02029521 (ClinicalTrials.gov)	March 2011	30/12/2013	Supplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis Patients	Supplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis for Growth Failure	Cystic Fibrosis	Dietary Supplement: Oral reduced l-glutathione;Dietary Supplement: Placebo	Clark Bishop	NULL	Completed	18 Months	10 Years	All	47	N/A	Italy
2	NCT01450267 (ClinicalTrials.gov)	June 2010	30/9/2011	Inhaled Glutathione (GSH) Versus Placebo in Cystic Fibrosis	Randomized, Single Blind, Controlled Trial of Inhaled Glutathione Versus Placebo in Patients With Cystic Fibrosis	Cystic Fibrosis	Drug: Inhaled Reduced Glutathione;Drug: Physiological solution	Serafino A. Marsico	Federico II University	Recruiting	6 Years	45 Years	Both	150	Phase 3	Italy
3	NCT00506688 (ClinicalTrials.gov)	July 2007	24/7/2007	Efficacy and Safety Study of Inhaled Glutathione in Cystic Fibrosis Patients	Randomized, Placebo-controlled, Double-blinded Study to Investigate the Efficacy and Safety of a 24-week Inhalation Treatment With Glutathione in Cystic Fibrosis Patients	Cystic Fibrosis	Drug: reduced glutathione sodium salt;Drug: 0.9% normal saline (control)	Mukoviszidose Institut gGmbH	Cystic Fibrosis Foundation Therapeutics	Completed	8 Years	N/A	Both	153	Phase 2	Germany
4	EUCTR2005-003870-88-DE (EUCTR)	20/10/2006	28/08/2006	Randomized, placebo-controlled, double-blind study to investigate the efficacy and safety of a 24-week inhalation treatment with glutathione in cystic fibrosis patients - GSH-4	Randomized, placebo-controlled, double-blind study to investigate the efficacy and safety of a 24-week inhalation treatment with glutathione in cystic fibrosis patients - GSH-4	Cystic fibrosis (CF) is the most common autosomal recessive lethal hereditary disorder in Caucasians. The majority of cystic fibrosis patients die as a result of progressive pulmonary disease. Airway inflammation, characterized by an excessive and persistent neutrophilic infiltration, is key for the pathogenesis of CF lung disease, and ultimately leads to lung destruction.	Product Name: GSH (Glutathione) Product Code: TAD 600 INN or Proposed INN: Glutathione Other descriptive name: reduced glutathione	Mukoviszidose Institut gGmbH i. G.	NULL	Not Recruiting			Female: yes Male: yes	160		Germany